Grasp the latest information from Olin and understand the new trends in the industry.
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
On December 11, 2025, Mr. Matthew Fosbery, Deputy Commercial Consul of Australia in Chengdu and Trade & Investment Commissioner of Austrade, and Ms. Wang Ming, Commercial Officer of Austrade, visited Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) for inspection and exchanges, and had in-
On September 8, 2025, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and Jiangsu Provincial Center for Disease Control and Prevention (hereinafter referred to as “Jiangsu Provincial CDC”) officially signed a strategic cooperation framework agreement in Chengdu. Centered on the core principles of “Technology-
Recently, the Recombinant Five-antigen Staphylococcus Aureus Vaccine (rFSAV), a Class 1.1 New Drug co-developed by Chengdu Olymvax Biopharmaceuticals Inc.
On April 2, 2025, Mr. Fabio Schina, Consul General of Italy in Chongqing, and his entourage visited Olymvax and had in-depth exchanges with the Company’s senior management on the cooperation prospects in the biomedical field.
Recently, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax” or the “Company”) successfully held the Kick-off Meeting & Investigator Training for Phase I Clinical Trials of Trivalent & Quadrivalent Influenza Virus Split Vaccines (MDCK Cells) in Xiangyun County, Xiangyun County, Dali Bai Autonomous Prefecture, Yunnan Province, marking new progress for the Company in the field of viral vaccines.